Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) has issued an announcement.
ConvaTec Group PLC announced the purchase of 2,623,293 ordinary shares as part of its $300 million share buyback program initiated in August 2025. This transaction is intended to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing earnings per share and improving the company’s market position.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £273.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, specializing in products and services for wound care, ostomy care, continence and critical care, and infusion care. The company focuses on improving the lives of people with chronic conditions and is a significant player in the healthcare market.
Average Trading Volume: 7,400,390
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.84B
Find detailed analytics on CTEC stock on TipRanks’ Stock Analysis page.